Importance Renal impairment confers an increased risk of stroke, bleeding, and death in
patients with atrial fibrillation. Little is known about the efficacy and safety of apixaban in …

Aims Atrial fibrillation (AF) is common among patients with impaired renal function.
Apixaban, a novel oral anticoagulant with partial renal excretion, was compared with …

Background: Compared with the general population, patients with advanced chronic kidney
disease have a> 10-fold higher burden of atrial fibrillation. Limited data are available …

BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are
inconsistent between the US Food and Drug Administration and European Medicines …

BACKGROUND: Apixaban is superior to aspirin for the prevention of stroke in patients with
atrial fibrillation. Apixaban is partially renally excreted and may accumulate in patients with …

Background: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from
clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised …

Background: Lifelong oral anticoagulation, either with warfarin or a non–vitamin K
antagonist oral anticoagulant (NOAC), is indicated for stroke prevention in most patients with …

Background: There are no randomized data evaluating the safety or efficacy of apixaban for
stroke prevention in patients with end-stage kidney disease on hemodialysis and with atrial …

Importance In the Apixaban for Reduction of Stroke and Other Thromboembolic
Complications in Atrial Fibrillation (ARISTOTLE) trial, the standard dose of apixaban was 5 …

Apixaban in patients with impaired renal function is supported by limited data. Landmark
clinical trials evaluating apixaban in patients with atrial fibrillation and/or acute venous …